Structure-guided residence time optimization of a dabigatran reversal agent

Felix Schiele(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Daniel Seeliger(Boehringer Ingelheim (Germany)), Tobias Litzenburger(Boehringer Ingelheim (Germany)), Joanne van Ryn(Boehringer Ingelheim (Brazil)), Michael Ritter
DORA PSI (Paul Scherrer Institute)
January 1, 2015
Cited by 0

Related Papers

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383